Hims subscribers in Q3
Short Answer
Both the model and the market expect Hims subscribers in Q3 2026 to be Above 2.95 million, with no compelling evidence of mispricing.
1. Executive Verdict
- Outcomes above 2.95 million are supported by strong Q2 2026 subscriber additions.
- AI/GLP-1 strategies are expected to boost future acquisition, facing macroeconomic headwinds.
- Hims added over 300,000 net new subscribers in Q2 with improved efficiency.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Above 2.95 million | 0.0% | 1.0% | Research does not highlight strong supporting evidence. |
| Above 3 million | 0.0% | 0.8% | Research does not highlight strong supporting evidence. |
| Above 3.05 million | 0.0% | 0.6% | Research does not highlight strong supporting evidence. |
| Above 3.1 million | 0.0% | 0.4% | Research does not highlight strong supporting evidence. |
| Above 3.15 million | 0.0% | 0.3% | Research does not highlight strong supporting evidence. |
Current Context
Hims & Hers Q3 2026 subscriber data remains unavailable. As of August 11, 2026, the company recently reported its Q2 2026 financial results on August 10, 2026. The third quarter concludes on September 30, 2026 [^][^][^][^]. In Q2 2026, Hims & Hers' subscriber count reached nearly 2.9 million, a 19% increase year-over-year [^][^].
Hims & Hers reported robust Q2 revenue with a net loss. Q2 2026 revenue was $753.2 million, up 38% year-over-year [^][^]. The company posted a net loss of $86.3 million, partly due to restructuring costs and a strategic pivot towards branded GLP-1 weight-loss drugs [^][^]. Hims & Hers raised its full-year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion [^][^].
The company is advancing AI-driven care and R&D initiatives. Recent developments include the launch of an AI-native care experience for Hers weight-loss members [^][^]. Hims & Hers also announced a multi-year investment in AI research and development, which includes establishing a new facility in Menlo Park [^][^].
2. Market Behavior & Price Dynamics
Historical Price (Probability)
Outcome probability
Date
This market's price action is defined by a single, sharp upward revision. The contract opened at a 1.0% probability before spiking 81 percentage points to 82.0% on August 11, 2026. This repricing was a direct reaction to Hims & Hers' Q2 2026 financial results, which were announced around August 10. The report disclosed 2.891 million subscribers as of June 30, with 300,000 net new additions in the quarter. This figure places the company within close striking distance of the contract's 2.95 million Q3 subscriber threshold, driving the perceived probability of success from near-zero to highly likely.
The market has zero traded volume, indicating that the price movement reflects an adjustment by market makers based on new fundamental data, not active trading between participants. The lack of liquidity means there is no meaningful support or resistance level established by two-way order flow. The current price of 82.0% serves as the effective ceiling. Sentiment is decisively positive, pricing in a high probability that the Q2 subscriber momentum will carry through Q3 and surpass the 2.95 million mark. However, this conviction has not been tested by significant capital.
3. Significant Price Movements
Notable price changes detected in the chart, along with research into what caused each movement.
📈 August 11, 2026: 81.0pp spike
Price increased from 1.0% to 82.0%
Outcome: Above 2.95 million
What happened: The primary driver of the prediction market price movement was Hims & Hers Health's robust Q2 2026 financial results, released around August 10-11, 2026 [^][^]. The company announced 2.891 million subscribers as of June 30, 2026, and a substantial addition of 300,000 net new subscribers during Q2 [^][^][^]. This strong performance made the "Above 2.95 million" subscriber target for Q3 significantly more probable, as it demonstrated consistent growth that would likely exceed the remaining approximately 59,000 subscribers needed to reach the threshold in Q3 [^][^][^]. Social media activity was not identified as a primary driver or significant accelerant based on the provided research.
4. Market Data
Contract Snapshot
This Kalshi market resolves "Yes" if Hims reports a number of subscribers in Q3 above the specific threshold for each contract (e.g., 'Above 3.1 million'); otherwise, a "No" resolution occurs if the subscriber count is at or below that threshold. Trading for the market concludes on November 2, 4:00 PM EST. The maximum payout date for settled contracts is March 3, 2027, and no other special settlement conditions are detailed.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Above 2.95 million | $0.99 | $0.14 | 0% |
| Above 3 million | $0.96 | $0.28 | 0% |
| Above 3.05 million | $0.78 | $0.50 | 0% |
| Above 3.1 million | $0.60 | $0.58 | 0% |
| Above 3.15 million | $0.34 | $0.95 | 0% |
| Above 3.2 million | $0.20 | $0.97 | 0% |
| Above 3.25 million | $0.18 | $0.99 | 0% |
Market Discussion
Hims & Hers announced 2.891 million total subscribers as of August 10, 2026, for its Q2 2026 earnings report, reflecting a 19% year-over-year increase [^][^]. Ahead of the Q2 report, investor focus on subscriber metrics was high, with prediction markets tracking growth expectations and social media showing bearish sentiment [^][^][^][^]. For Q3 2026, the company has provided revenue guidance of $880 million to $900 million and raised its full-year 2026 revenue outlook, with investors also monitoring its strategic pivot toward weight loss and international expansion for future subscriber trends [^][^][^][^].
5. How might the new AI-native care experience and expanded GLP-1 offerings impact Hims' customer acquisition and retention in Q3 2026?
| Q2 2026 Subscribers | Nearly 2.9 million [^][^][^] |
|---|---|
| Q2 2026 Subscriber Additions | 300,000 [^] |
| Q3 2026 Revenue Guidance | $880 million to $900 million [^][^] |
Hims & Hers has not yet released its Q3 2026 subscriber numbers, so the exact impact is currently unknown [^] [^] [^] [^] . However, the company’s strategic initiatives, including an AI-native care experience and expanded GLP-1 offerings, are expected to significantly boost both customer acquisition and retention into Q3. These efforts aim to enhance user engagement, reduce support friction, and broaden the product funnel [^][^][^][^]. For Q3 2026, Hims has projected revenue guidance of $880 million to $900 million, indicating anticipated continued growth as these new AI and product initiatives scale [^][^].
The AI-native care experience is already improving user engagement and operational efficiency. Management reported that users sent three times more messages, with AI handling 80% of questions, and non-clinical support work decreasing by nearly 50% [^]. These improvements in engagement and reduced service friction are anticipated to bolster retention and potentially improve conversion rates for new users [^][^][^][^]. The company expects AI investments to yield benefits within 12–18 months through improved experiences, reduced cancellations, and lower service costs [^]. Early data from immersive app experiences and AI tools have already indicated lower cancellation rates among participating subscribers, directly contributing to better retention [^][^][^][^][^].
Prioritizing GLP-1s has significantly strengthened Hims' financial forecasts and subscriber growth. Hims & Hers' transition in early 2026 to prioritize FDA-approved GLP-1 medications contributed to a raised full-year 2026 revenue forecast of $3.1–$3.3 billion [^][^][^]. Strong demand for branded weight-loss treatments supported Q2 growth, with retention rates in these cohorts aligning with expectations [^]. This strategic focus on GLP-1s is helping to attract new subscribers and improve their longevity with the service [^][^][^][^]. The company ended Q2 2026 with nearly 2.9 million subscribers, adding 300,000 new subscribers in the quarter, demonstrating strong momentum into Q3 [^][^][^].
6. How did Hims & Hers' subscriber growth rate in Q2 2026 compare against telehealth competitor Ro?
| Total Subscribers | 2.9 million (Q2 2026) [^][^][^] |
|---|---|
| YoY Subscriber Growth | 19% (Q2 2026) [^][^][^] |
| Reporting Period | Q2 2026 [^][^][^] |
Hims & Hers reported significant subscriber growth and high total subscribers in Q2 2026. In Q2 2026, Hims & Hers Health reported nearly 2.9 million total subscribers, demonstrating a 19% year-over-year subscriber growth for the company [^][^][^]. For subsequent periods like Q3 2026, prediction markets monitoring Hims & Hers' subscriber counts identify enterprise adoption as a key performance indicator [^].
A direct comparison with Ro's growth is not possible. Based on the information provided, a direct comparison of Hims & Hers' subscriber growth rate against that of its telehealth competitor Ro cannot be made. Details regarding Ro's subscriber growth rate are not available, precluding such an analysis.
7. What do recent trends in Hims & Hers' marketing spend and customer acquisition cost (CAC) imply for Q3 2026 subscriber growth?
| Q2 2026 Subscribers | nearly 3 million [^] |
|---|---|
| Q2 2026 Net New Subscribers | over 300,000 [^] |
| Q3 2026 Revenue Expectation | $880 million to $900 million [^] |
Hims & Hers achieved strong Q2 2026 subscriber growth and efficiency. The company added over 300,000 net new subscribers during the quarter, bringing its total subscriber base to nearly 3 million [^]. Simultaneously, marketing spend as a percentage of revenue improved, decreasing to 34% in Q2 2026. This represents a 5-percentage-point year-over-year improvement and a 2-percentage-point sequential improvement, demonstrating enhanced marketing effectiveness [^].
Management anticipates continued growth into Q3 2026 and beyond. Hims & Hers projects Q3 2026 revenue to be between $880 million and $900 million, a notable increase from the $753 million reported in Q2 2026 [^]. This expected growth is driven by sustained demand for new weight-loss offerings and other expanded categories. Furthermore, AI-driven initiatives are forecasted to improve subscriber experiences, reduce churn, and lower operational costs, with an estimated payback period of 12 to 18 months, reinforcing the outlook for sustained subscriber growth into Q3 2026 and beyond [^].
8. What does alternative data, like web traffic and mobile app downloads, show about Hims' new user momentum in Q3 2026?
| Projected Q3 2026 Revenue | $880 million to $900 million (August 11, 2026) [^][^] |
|---|---|
| Full-Year 2026 Revenue Outlook | $3.1 billion to $3.3 billion (August 11, 2026) [^][^] |
| Q2 2026 Subscriber Growth | Over 300,000 new subscribers, nearly 3 million total (Q2 2026) [^] |
Specific alternative data for Hims' Q3 2026 new user momentum is unavailable. The provided research does not include specific alternative data, such as web traffic or mobile app downloads, to demonstrate Hims' new user momentum in the third quarter of 2026 [^][^]. While Hims & Hers utilizes its mobile app for growth and retention, and a potential platform rollout in Q3 2026 is viewed as a catalyst for customer acquisition, the requested specific data is not present in the provided facts [^][^]. General discussions indicate that alternative data can be used to determine creditworthiness and inform investment decisions [^][^][^][^], but this information does not pertain to Hims' specific new user momentum for Q3 2026.
Hims & Hers projects strong Q3 2026 revenue and increased full-year outlook. As of August 11, 2026, the company projected Q3 2026 revenue to be between $880 million and $900 million [^]. Additionally, Hims & Hers raised its full-year 2026 outlook to $3.1 billion to $3.3 billion [^][^]. In the second quarter of 2026, the company reported adding over 300,000 subscribers, bringing its global subscriber base to nearly 3 million people [^].
The company focuses on mobile app and platform expansion for growth. Hims & Hers continues to drive growth and retention through its mobile app, condition-specific content hubs, and a clinical-empathy-based telehealth experience designed to foster customer loyalty [^]. The potential full rollout of the Hims & Hers Benefits platform in Q3 2026 is considered a major de-risking catalyst for customer acquisition, with enterprise expansion serving as a primary engine for growth [^].
9. Which specific economic headwinds or tailwinds, such as consumer discretionary spending trends, pose the greatest risk to Hims' Q3 subscriber targets?
| Total Subscribers | Approximately 2.9 million as of Q2 2026 [^][^] |
|---|---|
| Historical Subscriber Growth | About 35% for 16 straight quarters [^] |
| Primary Economic Risk | Macroeconomic pressure on consumer discretionary spending [^] |
Macroeconomic pressure on discretionary spending poses the greatest risk. The primary economic risk to Hims' subscriber targets is the impact of macroeconomic pressures on consumer discretionary spending, particularly as wellness and healthcare products may be perceived as non-essential during difficult economic periods [^]. Consumer spending is significantly influenced by factors such as weak paychecks [^][^] and the overall health of consumer credit [^], both of which are crucial indicators of broader economic stability and consumer behavior.
Operational risks and slowing growth challenge subscriber targets. Hims has also navigated specific operational challenges, including transitions within its sexual health business and potential volatility in the shipment cadences for weight-loss products, which have previously created headwinds for subscriber growth [^][^]. Despite these operational challenges, Hims & Hers reported approximately 2.9 million subscribers as of Q2 2026 [^][^]. While the company maintained a strong subscriber growth rate of about 35% for 16 consecutive quarters, this growth has noticeably slowed in the last two quarters [^].
10. What Could Change the Odds
Key Catalysts
Hims & Hers reported 2.891 million subscribers at the end of Q2 2026, representing 19% year-over-year growth [^] [^] [^] . Reports Second Quarter 2026..." data-source-lanes="traditional">[^][^][^]. For Q3 2026, the company guided for revenue of $880 million and adjusted EBITDA in the range of $75 million to $95 million [^][^]. Bullish catalysts include the expansion of the Novo Nordisk partnership for branded weight-loss products, successful integration of the Eucalyptus acquisition, which closed in June 2026, and potential monetization of the company's peptide facility [^][^][^].
Bearish risks center on regulatory uncertainty regarding peptide compounding, specifically FDA advisory committee proceedings, and FTC scrutiny [^] [^] [^] . Is the Rebound Justified? | TIKR.com" data-source-lanes="traditional">[^][^]. Further concerns include potential subscriber churn as subscription fees adjust, and margin compression from the shift toward lower-margin weight-loss and international operations [^]. Hims & Hers Q2 2026 earnings were reported on August 10, 2026; Q3 2026 financial results are typically reported in early November [^][^][^].
Key Dates & Catalysts
- Expiration: March 03, 2027
- Closes: March 03, 2027
11. Decision-Flipping Events
- Trigger: Hims & Hers reported 2.891 million subscribers at the end of Q2 2026, representing 19% year-over-year growth [^] [^] [^] .
- Trigger: For Q3 2026, the company guided for revenue of $880 million and adjusted EBITDA in the range of $75 million to $95 million [^] [^] .
- Trigger: Bullish catalysts include the expansion of the Novo Nordisk partnership for branded weight-loss products, successful integration of the Eucalyptus acquisition, which closed in June 2026, and potential monetization of the company's peptide facility [^] [^] [^] .
- Trigger: Bearish risks center on regulatory uncertainty regarding peptide compounding, specifically FDA advisory committee proceedings, and FTC scrutiny [^] [^] [^] .
13. Historical Resolutions
Historical Resolutions: 15 markets in this series
Outcomes: 11 resolved YES, 4 resolved NO
Recent resolutions:
- KXHIMS-26AUGSUBS-3040000: NO (Aug 10, 2026)
- KXHIMS-26AUGSUBS-3000000: NO (Aug 10, 2026)
- KXHIMS-26AUGSUBS-2960000: NO (Aug 10, 2026)
- KXHIMS-26AUGSUBS-2920000: NO (Aug 10, 2026)
- KXHIMS-26AUGSUBS-2880000: YES (Aug 10, 2026)
